MedTrace Logo

Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities

NCT04584892 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2023-11-28

No results posted yet for this study

Summary

This is a study on Italian patients with haemophilia A in prophylaxis treatment with Turoctocog alfa under routine clinical conditions. The purpose of the study is to investigate the therapeutic scheme in a population of patients treated with Turoctocog alfa and to investigate the participation in recreational activities, the level of physical activity, and quality of life. Participants will get NovoEight® (Turoctocog alfa) as prescribed to them by the study doctor. The study will last for about 12 months. Participants will be requested to fill in the Questionnaires investigating the participation in recreational activities, the level of physical activity, and quality of life.

Conditions

  • Haemophilia A

Interventions

DRUG

Turoctocog alfa

Patients will be treated with commercially available NovoEight® (turoctocog alfa) according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available NovoEight® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.

Sponsors & Collaborators

Principal Investigators

  • Clinical Reporting Anchor and Disclosure 1452 · Novo Nordisk A/S

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-12
Primary Completion
2023-03-27
Completion
2023-03-27

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04584892 on ClinicalTrials.gov